These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31958450)

  • 1. Establishment of an anti-hepatitis C virus IgG avidity test for dried serum/plasma spots.
    Eshetu A; Hauser A; An der Heiden M; Schmidt D; Meixenberger K; Ross S; Obermeier M; Ehret R; Bock CT; Bartmeyer B; Bremer V; Bannert N
    J Immunol Methods; 2020 Apr; 479():112744. PubMed ID: 31958450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots.
    Shepherd SJ; Kean J; Hutchinson SJ; Cameron SO; Goldberg DJ; Carman WF; Gunson RN; Aitken C
    J Clin Virol; 2013 May; 57(1):29-35. PubMed ID: 23369886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype.
    Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ
    J Med Virol; 2018 Jan; 90(1):120-130. PubMed ID: 28843002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a BioRad Avidity assay for identification of recent HIV-1 infections using dried serum or plasma spots.
    Hauser A; Heiden MA; Meixenberger K; Han O; Fiedler S; Hanke K; Koppe U; Hofmann A; Bremer V; Bartmeyer B; Kuecherer C; Bannert N
    J Virol Methods; 2019 Apr; 266():114-120. PubMed ID: 30738741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody avidity-based approach to estimate population-level incidence of hepatitis C.
    Boon D; Bruce V; Patel EU; Quinn J; Srikrishnan AK; Shanmugam S; Iqbal S; Balakrishnan P; Sievers M; Kirk GD; Thomas DL; Quinn TC; Cox AL; Page KA; Solomon SS; Mehta SH; Laeyendecker O
    J Hepatol; 2020 Aug; 73(2):294-302. PubMed ID: 32240715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.
    Patel EU; Cox AL; Mehta SH; Boon D; Mullis CE; Astemborski J; Osburn WO; Quinn J; Redd AD; Kirk GD; Thomas DL; Quinn TC; Laeyendecker O
    J Infect Dis; 2016 Aug; 214(3):344-52. PubMed ID: 26768250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection.
    Gaudy-Graffin C; Lesage G; Kousignian I; Laperche S; Girault A; Dubois F; Goudeau A; Barin F
    J Clin Microbiol; 2010 Sep; 48(9):3281-7. PubMed ID: 20610669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two immunoassays for concurrent detection of HCV antigen and antibodies among HIV/HCV co-infected patients in dried serum/plasma spots.
    Eshetu A; Hauser A; Schmidt D; Bartmeyer B; Bremer V; Obermeier M; Ehret R; Volkwein A; Bock CT; Bannert N
    J Virol Methods; 2020 May; 279():113839. PubMed ID: 32087189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody.
    Ward KN; Dhaliwal W; Ashworth KL; Clutterbuck EJ; Teo CG
    J Med Virol; 1994 Aug; 43(4):367-72. PubMed ID: 7525865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index.
    Coppola N; Pisapia R; Tonziello G; Masiello A; Martini S; Pisaturo M; Messina V; Sagnelli C; Macera M; Signoriello G; Sagnelli E
    J Clin Virol; 2009 Nov; 46(3):222-9. PubMed ID: 19758839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.
    Kanno A; Kazuyama Y
    J Med Virol; 2002 Oct; 68(2):229-33. PubMed ID: 12210412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous detection of hepatitis C virus antigen and antibodies in dried blood spots.
    Brandão CP; Marques BL; Marques VA; Villela-Nogueira CA; Do Ó KM; de Paula MT; Lewis-Ximenez LL; Lampe E; Sá Ferreira JA; Villar LM
    J Clin Virol; 2013 Jun; 57(2):98-102. PubMed ID: 23518440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z; Mbwambo J; Shimakawa Y; Poiteau L; Chevaliez S; Pawlotsky JM; Rwegasha J; Bhagani S; Taylor-Robinson SD; Makani J; Thursz MR; Lemoine M
    J Int AIDS Soc; 2017 Sep; 20(1):21856. PubMed ID: 28953324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots.
    Judd A; Parry J; Hickman M; McDonald T; Jordan L; Lewis K; Contreras M; Dusheiko G; Foster G; Gill N; Kemp K; Main J; Murray-Lyon I; Nelson M
    J Med Virol; 2003 Sep; 71(1):49-55. PubMed ID: 12858408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: performance of dried blood spots for hepatitis C antibodies detection.
    Muzembo BA; Mbendi NC; Nakayama SF
    Public Health; 2017 Dec; 153():128-136. PubMed ID: 29035801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.
    Klimashevskaya S; Obriadina A; Ulanova T; Bochkova G; Burkov A; Araujo A; Stramer SL; Tobler LH; Busch MP; Fields HA
    J Clin Microbiol; 2007 Oct; 45(10):3400-3. PubMed ID: 17715377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating prevalence from dried blood spots without using biological cut-offs: application of a novel approach to hepatitis C virus in drug users in France (ANRS-Coquelicot survey).
    Léon L; Pillonel J; Jauffret-Roustide M; Barin F; Le Strat Y
    Epidemiol Infect; 2019 Jan; 147():e220. PubMed ID: 31364569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.
    Kania D; Bekalé AM; Nagot N; Mondain AM; Ottomani L; Meda N; Traoré M; Ouédraogo JB; Ducos J; Van de Perre P; Tuaillon E
    Clin Microbiol Infect; 2013 Dec; 19(12):E533-41. PubMed ID: 23902574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    Neesgaard B; Ruhwald M; Krarup HB; Weis N
    PLoS One; 2018; 13(7):e0201629. PubMed ID: 30063765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections.
    Odari EO; Budambula NL; Nitschko H
    Ethiop J Health Sci; 2014 Oct; 24(4):343-52. PubMed ID: 25489199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.